Status:
TERMINATED
Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris
Lead Sponsor:
Jacobus Pharmaceutical
Conditions:
Pemphigus Vulgaris
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of this 12-month study was to determine the efficacy of dapsone as a glucocorticoid-sparing agent in maintenance phase pemphigus vulgaris.
Detailed Description
Patients were entered into the trial on steroids in combination with cytotoxic agents as needed. The steroid dose was the lowest dose at which the patient's disease was controlled before the last flar...
Eligibility Criteria
Inclusion
- Histologic evidence compatible with pemphigus vulgaris and direct immunofluorescence evidence of pemphigus vulgaris.
- Chronic disease that has been controlled with steroids and/or cytotoxics, e.g. maintenance phase.
- On prednisone 15 or more mg/day to around 40 mg/day or on prednisone 15 or more mg every other day (qod) to around 40 mg qod.
- Failure to taper steroids below a range of 15 mg/day to around 40 mg/day or 15 mg/qod to around 40 qod without flaring the disease.
- The steroid dosage at which the most recent flare occurred should not be less than 85% of the last (within 30 days) dosage which controlled the disease, i.e. 85% of the baseline steroid dosage. This is to ensure that patients will not have had a recent acute flare at the time of entry into the study, and be in the rapid steroid taper portion of their disease after such a flare.
- Two baseline steroid dosages as determined by prior flares. It is common that patients will be repetitively unable to taper below a certain baseline steroid dose without experiencing a mild flare of their disease. This baseline dose will be determined on two occasions during attempted tapers, and the baseline number then averaged to determine the dose of steroid the patient is on at the time of entry into the study.
- No pulse steroids, pulse cyclosphosphamide, or plasmapheresis within two months of beginning the protocol. This will exclude patients who had recent acute flares of their disease and may be on the rapid steroid taper portion of their disease. The patient must be in maintenance phase, as defined in the criteria listed in e.
- Patient understands the procedures and agrees to participate in the study program by giving written informed consent.
Exclusion
- Patients able to taper steroids without recurrence of disease.
- Patients with early, severe disease that have not responded to high doses of prednisone, cytotoxics, plasmapheresis, or other modalities.
- Contraindications to the use of Dapsone, including severe anemia or G6PD deficiency.
- Patient has behavioral problems that might interfere with compliance.
- Pregnancy or breast-feeding.
- Younger than 18 or older than 80 years of age. Since PV is rare in patients younger than 18, it was decided to exclude this potentially different population. It is unlikely that this will exclude many patients. Dapsone induces a hemolytic anemia, which would be a particular problem for patients over age 80, who are more likely to have ischemic heart disease or other atherosclerotic vascular disease.
- History of allergy to dapsone.
- Ischemic heart disease
Key Trial Info
Start Date :
November 1 1996
Trial Type :
INTERVENTIONAL
End Date :
February 1 2004
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00429533
Start Date
November 1 1996
End Date
February 1 2004
Last Update
February 5 2007
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University Medical Center
Chicago, Illinois, United States, 60611-3010
2
Rush-Presbyterian-St. Luke's Medical Center
Chicago, Illinois, United States, 60612
3
Henry Ford Hospital
Detroit, Michigan, United States, 48202
4
Cooper Hospital/University Medical Center
Camden, New Jersey, United States, 08103